SUNNYVALE, Calif., Dec. 12, 2019 /PRNewswire/ -- Timpanogos
Cancer Services made history in Utah recently with the installation of the
state's first Radixact® System, the next-generation
TomoTherapy® platform. Accuray Incorporated's (NASDAQ:
ARAY) Radixact System is one of the most versatile systems
available, enabling the administration of radiation using a range
of delivery methods including image-guided, intensity-modulated
radiation therapy (IG-IMRT) and stereotactic body radiation therapy
(SBRT), that provide the hospital's clinical team with the
flexibility to offer a personalized and precise treatment approach
to almost anyone requiring treatment with radiation.
Timpanogos Cancer Services is part of the MountainStar
Healthcare family of hospitals, a division of Hospital Corporation
of America (HCA). Being part of this vast, nearly 300-hospital
network helps Timpanogos Regional Hospital to achieve its goal of
offering the highest quality of care to its patients.
Following a ribbon-cutting ceremony to commemorate the Radixact
System installation, James W. Clarke
M.D., a board certified radiation oncologist and Timpanogos
Cancer Services director, shared how he believes the system will
benefit the hospital's patients. "The Radixact System will enable
our team to truly provide our patients with the best treatment for
them. The treatment planning and delivery capabilities of the
system allow for the highest level of precision with maximal
sparing of the nearby normal tissues. The system's unique hardware
and software will facilitate the treatment of organ-confined
tumors, locally advanced tumors and metastatic tumors. It will also
provide us with the tools to assess whether adaptation of radiation
delivery during the course of treatment is needed because of
changes in tumor size and patient anatomy. We look forward to using
the Radixact System to efficiently deliver precise and accurate
radiation treatments to more patients each day."
"We are proud to have the opportunity to partner with the
Timpanogos Cancer Services clinical team to help advance cancer
care in Utah. The response from
our Radixact System users has been overwhelmingly positive as they
have been able to expand patient access to precision radiation
therapy, enabling previously untreatable cases to be treated with
ease – and with a single, seamless process," said Joshua H. Levine, president and CEO at Accuray.
"The unique Radixact System technology facilitates the delivery of
both conventionally fractionated and hypofractionated radiation
therapy treatments on a single platform, enabling the clinical team
to treat a wide range of cancer cases. We believe this will be
extremely valuable as reimbursement models shift favoring
hypofractionation, when clinically appropriate. With the
installation of the Radixact System, the Timpanogos team is well
positioned to achieve their goal of providing world class radiation
therapy treatments to their growing patient base."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please
visit www.accuray.com or follow us
on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences, patient outcomes, shifts in
reimbursement models, and the company's ability to continue to
penetrate the global radiation therapy market. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties
include, but are not limited to, the company's ability to achieve
widespread market acceptance of its products; reimbursement models
not favoring hypofractionation; the company's ability to develop
new products or improve existing products to meet customers' needs;
the company's ability to anticipate or keep pace with changes in
the marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's quarterly report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
November 6, 2019, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth
Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/timpanogos-cancer-services-first-in-utah-to-offer-precise-and-accurate-radiation-treatments-with-the-accuray-radixact-system-300973721.html
SOURCE Accuray Incorporated